MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid, is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.

Institution	Shares	Value	Change
Investor AB	872,093	$13M	UNCHANGED
Yelin Lapidot Holdings Management Ltd	758,169	$11M	DECREASED
Rosalind Advisors	749,054	$11M	UNCHANGED
T. Rowe Price	641,075	$9M	DECREASED
BlackRock	525,929	$8M	INCREASED

MediWound Ltd. (MDWD) Ownership & Trading Activity

Top Institutional Holders